A study assessing safety of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention.
Latest Information Update: 23 Jul 2018
Price :
$35 *
At a glance
- Drugs Bivalirudin (Primary) ; Heparin
- Indications Acute coronary syndromes; Thrombosis
- Focus Adverse reactions
- 08 Oct 2016 New trial record